Ainos, Inc.
AIMDAinos, Inc. in brief
Ainos, Inc. is a listed company in the Biotechnology industry, based in Houston, Texas, USA. Its market value was $6 M on 26 October 2026, which makes it the 26,616th largest listed company in the world and the 4,373rd largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $15 M. It employs about 41 people and Chun-Hsien Tsai is its chief executive. Its shares trade under the symbol AIMD (Nasdaq).
Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.
About Ainos, Inc.
Ainos, Inc., incorporated in the State of Texas in 1984, is a dual-platform company advancing artificial intelligence–based smelltech technologies and immune therapeutics. Our primary strategic focus is the commercialization of our proprietary scent digitization platform, AI Nose, while we also continue to develop therapeutic assets based on our low-dose oral interferon program, VELDONA®.
Our core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which we refer to as a smell language model, to digitize scent and volatile organic compound signals into Smell ID, a machine-readable data format. AI Nose is initially developed in healthcare-related settings, including point-of-care testing. These early healthcare applications shaped the platform’s sensor architecture, data models, and system calibration.
From the company's annual report filed with the US SEC: read the report
Ainos, Inc. timeline
- 1996
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2021
- ✎Renamed Ainos, Inc.Formerly Amarillo Biosciences Inc.
- 2022
- 💰Record revenue of $4 millionFY2022, the highest of the 7 years on record.
Events of Ainos, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,501 (Jan 2022) · #5,472 (Dec 2022) · #5,183 (Jul 2023) · #4,517 (Jan 2024) · #2,378 (Mar 2026) · #4,020 (Aug 2026) · #4,276 (Oct 2026) · #4,372 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 51.1×
- Price / book
- 0.8×
- Free cash flow yield
- -75.7%
- Net margin
- -12308.3%
- Operating margin
- -11658.3%
- Return on equity
- -195.4%
- Liabilities / assets
- 63.8%
- Revenue growth
- 0.0%
- R&D / revenue
- 6458.3%
- Revenue per employee
- $3 K
- Profit per employee
- $-360 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0M | — | $-14M | $-15M | -12308.3% |
| Dec 2024 | — | — | $-14M | $-15M | — |
| Dec 2023 | $0M | -96.6% | $-13M | $-14M | -11475.0% |
| Dec 2022 | $4M | +496.6% | $-14M | $-14M | -398.0% |
| Dec 2021 | $1M | +2850.0% | $-4M | $-4M | -659.3% |
| Dec 2020 | $0M | +100.0% | $-1M | $-1M | -7250.0% |
| Dec 2019 | $0M | -87.5% | $-2M | $-2M | -15800.0% |
| Dec 2018 | $0M | — | $-1M | $-1M | -1675.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-5M | $0M | $-5M | $-3.46 | — |
| Dec 2024 | $-6M | $0M | $-6M | $-7.82 | — |
| Dec 2023 | $-5M | $0M | $-5M | $-3.36 | — |
| Dec 2022 | $-3M | $1M | $-4M | — | — |
| Dec 2021 | $-1M | $0M | $-1M | $-0.03 | — |
| Dec 2020 | $-1M | $0M | $-1M | $-0.04 | — |
| Dec 2019 | $-1M | $0M | $-1M | $-0.04 | — |
| Dec 2018 | $-1M | $0M | $-1M | $-0.04 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $1M, net income $-2M. Lighter bars: fourth quarters worked out from the annual report.
SEC filings
- Nov 20, 20268-KCurrent reportListing notice
- Nov 17, 20268-KCurrent reportMaterial agreement · Regulation FD disclosure
- Nov 16, 202610-QQuarterly report · period to Sep 2026
- Nov 16, 20268-KCurrent reportResults of operations
- Nov 10, 2026DEF 14AProxy statement
- Oct 16, 20268-KCurrent reportBylaws amended · Other events
- Sep 28, 20268-KCurrent reportMaterial agreement · Regulation FD disclosure
- Aug 3, 20268-KCurrent reportResults of operations
- Aug 3, 202610-QQuarterly report · period to Jun 2026
- Jul 10, 20268-KCurrent reportAuditor change
- Jul 9, 20268-KCurrent reportNew financial obligation
- May 13, 202610-QQuarterly report · period to Mar 2026
Official filings of Ainos, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $0 M
- Operating income
- $-14 M
- Net income
- $-15 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $21 M
- Total liabilities
- $13 M
- Total equity
- $8 M
As of December-2025
Top 15 institutional investors in Ainos, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Geode Capital Management, LLC | 43,892 | -194 (-0.44%) | 0.59% | $0 M | Nov 6, 2026 |
| 2 | Vanguard Capital Management LLC | 33,939 | +17,915 (+111.80%) | 0.46% | $0 M | Nov 13, 2026 |
| 3 | Principal Securities, Inc. | 31,596 | New | 0.43% | $0 M | Nov 12, 2026 |
| 4 | Envestnet Asset Management Inc | 31,596 | New | 0.43% | $0 M | Nov 16, 2026 |
| 5 | Keystone Financial Group | 25,250 | -300 (-1.17%) | 0.34% | $0 M | Nov 12, 2026 |
| 6 | Mariner, LLC | 15,800 | 0 (0.00%) | 0.21% | $0 M | Nov 12, 2026 |
| 7 | Vanguard Fiduciary Trust Co | 14,169 | 0 (0.00%) | 0.19% | $0 M | Nov 13, 2026 |
| 8 | BlackRock, Inc. | 3,065 | 0 (0.00%) | 0.04% | $0 M | Nov 13, 2026 |
| 9 | Citigroup Inc | 1,702 | +1,525 (+861.58%) | 0.02% | $0 M | Nov 4, 2026 |
| 10 | Tower Research Capital LLC (TRC) | 1,683 | -1,474 (-46.69%) | 0.02% | $0 M | Nov 16, 2026 |
| 11 | Steward Partners Investment Advisory, LLC | 1,208 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 12 | Seneschal Advisors, LLC | 900 | -900 (-50.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 13 | Caitong International Asset Management Co., Ltd | 12 | -81 (-87.10%) | 0.00% | $0 M | Oct 29, 2026 |
| 14 | Barclays PLC | 3 | New | 0.00% | $0 M | Nov 6, 2026 |
| 15 | UBS Group AG | 2 | -4,590 (-99.96%) | 0.00% | $0 M | Nov 10, 2026 |
Mutual funds holding Ainos, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 48,596 | $0 M | 0.66% | <0.01% | +131% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 16,024 | $0 M | 0.22% | <0.01% | +73% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 2,049 | $0 M | 0.03% | <0.01% | +68% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 396 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
As of Jun 30, 2026
Insider trading at Ainos, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Yao-Chung ChiangDirector | Buyindirect | +3,500 | $2.050 | $7 K | 11,279 | Form 4 |
| filed | Yao-Chung ChiangDirector | Buyindirect | +2,000 | $2.130 | $4 K | 7,779 | Form 4 |
| filed | Yao-Chung ChiangDirector | Buyindirect | +250 | $2.300 | $575 | 5,779 | Form 4 |
| filed | Yao-Chung ChiangDirector | Buyindirect | +2,000 | $2.000 | $4 K | 5,529 | Form 4 |
| filed | Taiwan Carbon Nano Technology Corp10% owner | Sell | -41,000 | $2.360 | $97 K | 948,925 | Form 4 |
| filed | Ting-Chuan LeeDirector | Sell | -109,988 | $1.900 | $209 K | 807,417 | Form 4 |
| filed | Chun-Jung TsaiDirector | Sell | -27,718 | $1.870 | $52 K | 658,199 | Form 4 |
| filed | Chun-Jung TsaiDirector | Sell | -1,082 | $1.550 | $2 K | 685,917 | Form 4 |
Markets and events: Ainos, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Bankruptcy filing: (8-K); (8-K); (8-K); (8-K); (8-K)
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2013 | Q4 2013 | $0M |
Trading halts
- 2026-11-12 20:20 UTC, code LUDP, resumed 20:25 UTC
- 2026-11-12 17:06 UTC, code LUDP, resumed 17:11 UTC
- 2026-11-12 17:00 UTC, code LUDP, resumed 17:05 UTC
- 2026-11-12 16:54 UTC, code LUDP, resumed 16:59 UTC
- 2026-11-12 16:41 UTC, code LUDP, resumed 16:51 UTC
Fails to deliver
- : 83 shares at $0.81
- : 83 shares at $0.84
- : 78 shares at $0.88
- : 79 shares at $0.90
- : 675 shares at $0.93
Ainos, Inc. scorecard#
Passes 2 of the 14 checks that could be worked out: strongest in financial health (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 26, 2026.
Valuation1 of 5
Growth0 of 2
Profitability0 of 3
Financial health1 of 3
Shareholder returns0 of 1
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Ainos, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 124 | 21 | 122 | 3,520 | 595 | 17 | 12 | 78 | 251 | — | |
| Cost of revenue | 21 | 53 | 376 | 2,114 | 184 | 11 | 8.8 | 65 | 60 | — | |
| Gross profit | 103 | −32 | −254 | 1,405 | 410 | 5.3 | 3.0 | 13 | 191 | — | |
| Research and development | 7,750 | 8,414 | 7,317 | 6,846 | 1,921 | 0.4 | 53 | 33 | — | — | |
| Selling, general and administrative | 6,344 | 5,395 | 5,635 | 8,536 | 2,357 | 1,445 | 1,531 | 1,315 | 770 | 667 | |
| Operating expenses | 14,093 | 13,809 | 12,953 | 15,382 | 4,278 | 1,446 | 1,583 | 1,348 | 770 | — | |
| Operating income | −13,990 | −13,841 | −13,206 | −13,976 | −3,867 | −1,440 | −1,580 | −1,335 | −580 | −667 | |
| Interest expense and finance costs | 712 | 616 | 144 | 54 | 19r | 11 | — | 4.0 | 38 | 2.9 | |
| Other non-operating income (expense) | −780 | −1,021 | −563 | −30 | −21 | — | — | — | — | — | |
| Income before tax | −14,770 | −14,862 | −13,770 | −14,007 | −21 | −10 | — | — | — | — | |
| Income tax | 0.8 | 0.8 | 0.8 | 0 | — | 0 | 0 | — | — | 0 | |
| Net income including minority interests | — | — | — | 14,007 | 3,889 | — | — | — | — | — | |
| Net income attributable to shareholders | −14,771 | −14,863 | −13,771 | −14,007 | −3,889 | −1,451 | −1,581 | −1,339 | −617 | −670 | |
| Earnings per share, basic | -3.46 | -7.82r | -3.36 | — | -0.03 | -0.04 | -0.04 | -0.04 | -0.03 | -0.03 | |
| Earnings per share, diluted | -3.46 | -7.82r | -3.36 | — | -0.03 | -0.04 | -0.04 | -0.04 | -0.03 | -0.03 | |
| Shares, weighted average (basic) | 4.3 | 1.9r | 4.1 | — | — | — | — | — | — | — | |
| Shares, weighted average (diluted) | 4.3 | 1.9r | 4.1 | — | 113 | 41 | 40 | 36 | 23 | 20r | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 417 | 3,893 | 1,886 | 1,853 | 1,751 | 22 | 409 | 1,277 | 2,038r | 134 | |
| Receivables | 0.0 | 0.1 | 0.5 | 202 | 0 | 0 | — | — | — | — | |
| Inventory | 296 | 144 | 168 | 595 | 0r | 0r | 4.1 | — | 23 | 15 | |
| Other current assets | 426 | 301 | 420 | 196 | 466 | 51 | 32r | 27 | 24 | 76 | |
| Current assets | 1,139 | 4,338 | 2,473 | 2,846 | 2,218 | 76 | 445r | 1,303 | 2,084 | 262 | |
| Property, plant and equipment | 343 | 560 | 877 | 1,376 | 1,188 | 3.2 | 5.1r | 14 | 27 | 44 | |
| Other intangible assets | 19,226 | 23,748 | 28,283 | 32,807 | 37,329 | 181 | 146 | 146 | 182 | 156 | |
| Total assets | 20,871 | 28,820 | 31,842 | 37,109 | 40,822 | 260 | 597 | 1,464 | 2,294 | 463 | |
| Accounts payable | — | — | — | — | — | 146 | 209 | 115 | 159 | 169r | |
| Current liabilities | 1,079 | 3,955 | 1,337 | 2,473 | 30,595 | 1,099 | 753 | 734 | 1,823 | 1,273 | |
| Lease liabilities (non-current) | — | — | — | 8.1 | 30 | — | — | — | — | — | |
| Non-current liabilities | — | — | — | — | 30 | 0 | — | — | — | — | |
| Total liabilities | 13,309 | 13,304 | 7,394 | 2,481 | 30,625 | 1,099 | 753 | 734 | 1,823 | 1,273 | |
| Retained earnings | −67,520 | −52,749 | −37,886 | −24,116 | −10,109 | −6,220 | −4,770 | −3,188 | −1,884 | −1,267 | |
| Shareholders' equity | 7,563 | 15,516 | 24,448 | 34,628 | 10,197 | −838 | −157 | 730 | 471r | −810 | |
| Total equity | — | — | — | — | — | −838 | −157 | 730 | 471 | — | |
| Total liabilities and equity | 20,871 | 28,820 | 31,842 | 37,109 | 40,822 | 260 | 597 | 1,464 | 2,294 | 463 | |
| Shares outstanding | 5.8r | 3.1r | 4.7 | 4.0r | 9.6r | 42 | 41 | 39 | 23 | 22 | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 4,780 | 4,802 | 4,871 | 4,833 | 2,044 | 15 | 22 | 56 | 40 | 26 | |
| Share-based compensation | 1,728 | 3,543 | 1,115 | 6,422 | −11r | 150 | 0 | 100 | 106 | 0 | |
| Cash from operating activities | −4,615 | −5,808 | −4,695 | −3,041r | −1,250 | −500 | −909 | −1,009 | −485r | −521 | |
| Capital expenditure | −35 | −21 | −93 | −634 | −144 | 0 | −1.6 | −4.9 | — | −48 | |
| Intangible assets bought | — | — | — | — | −5,773 | −7.2 | −11 | −2.4 | −49 | −101 | |
| Cash from investing activities | −2.2 | −125 | −102 | −630 | −181 | −7.2 | −13 | −7.3 | −49 | −148 | |
| Shares issued | — | — | — | — | 46,000 | 0 | — | — | — | — | |
| Cash from financing activities | 1,008 | 8,026 | 4,924 | 3,851r | 3,154 | 120 | 55 | 255 | 2,438 | 782 | |
| Exchange-rate effect on cash | — | — | — | — | 5.4 | 0 | — | — | — | — | |
| Change in cash | −3,476 | 2,007 | 32 | 102 | 1,729r | −387 | −868 | −761 | 1,904r | 113 | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
As of Sep 30, 2026
Executive pay at Ainos, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Chun-Hsien Tsai | $916 K | $2.2 M | $325 K | — |
| 2024Chun-Hsien Tsai | $302 K | $21 K | $72 K | — |
| 2023Chun-Hsien Tsai | $1.3 M | $987 K | $161 K | — |
| 2022Chun-Hsien Tsai | $3.8 M | $778 K | $850 K | — |
| 2021Chun-Hsien Tsai | $63 K | $63 K | $201 K | $394 |
As of Dec 31, 2025
Events at Ainos, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 1 · Auditor changed 2 · Material agreement 5 · New debt 1 · Unregistered share sale 1 · Bylaws or fiscal year changed 2 · Shareholder vote 1 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Delisting notice | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| New debt | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Unregistered share sale | 8-K | |
| Shareholder voteResults announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K |
As of Nov 20, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Apr 2021 | $20 M | Private placement after listing | $10 to $50 million | — | equity | SEC |
How Ainos, Inc. compares in Biotechnology
- Market cap$6 M · higher than 7% of 726
- Revenue$0 M · higher than 17% of 648
- Price / sales51.1× · lower than 17% of 339
- Price / book0.8× · lower than 82% of 532
- FCF yield-75.7% · higher than 14% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Ainos, Inc.🇺🇸 | $6 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Oneness Biotech Co., Ltd.$520 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
How current the figures are
- Market cap:
- Oct 26, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 22, 2026
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Ainos, Inc.? Verify and update this profile — free
Show Ainos, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.